Report of Foreign Issuer (6-k)
September 21 2015 - 6:42AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of September 2015
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrants name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
On September 21, 2015 Fresenius Medical Care AG & Co. KGaA (the Company) issued an Investor News disclosing historic quarterly results for 2014 in conformity with disclosure changes made in 2015.
EXHIBITS
Exhibit 99.1 Investor News Release issued September 21, 2015.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: September 21, 2015
|
FRESENIUS MEDICAL CARE AG & Co. KGaA, |
|
a partnership limited by shares, represented by: |
|
|
|
FRESENIUS MEDICAL CARE MANAGEMENT AG, its |
|
general partner |
|
|
|
|
|
|
By: |
/s/ RICE POWELL |
|
|
|
|
|
|
|
Name: |
Rice Powell |
|
|
|
|
|
|
|
|
Title: |
Chief Executive Officer and |
|
|
|
|
Chairman of the Management Board |
|
|
|
|
of the General Partner |
|
|
|
|
|
By: |
/s/ MICHAEL BROSNAN |
|
|
|
|
|
Name: |
Michael Brosnan |
|
|
|
|
|
|
Title: |
Chief Financial Officer and |
|
|
|
Member of the Management Board |
|
|
|
of the General Partner |
|
|
|
|
|
|
|
3
Exhibit 99.1
Investor News |
|
Oliver Maier |
|
|
Head of Investor Relations |
|
|
|
|
|
Fresenius Medical Care |
|
|
Else-Kröner-Straße 1 |
|
|
61352 Bad Homburg |
|
|
Germany |
|
|
T +49 6172 609-2601 |
|
|
F +49 6172 609-2301 |
|
|
oliver.maier@fmc-ag.com |
|
|
www.freseniusmedicalcare.com |
|
|
|
September 21, 2015 |
|
|
Fresenius Medical Care provides historical segment data
Bad Homburg, Germany Fresenius Medical Care AG & Co. KGaA (the company or Fresenius Medical Care), the worlds largest provider of dialysis products and services, has aligned the disclosure of segments in the first quarter 2015. Hereinafter we provide an update of historical quarterly numbers for 2014.
An overview of the figures for 2014 reflecting the changes in the disclosure of the segments is available in the table on the next page. This Investor News will be published also on the Companys website www.freseniusmedicalcare.com in the section News.
Fresenius Medical Care is the worlds largest provider of products and services for individuals with renal diseases of which more than 2.6 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,421 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 289,610 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of additional medical services in the field of care coordination.
For more information about Fresenius Medical Care, visit the companys website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaAs reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Number prior year according to changes in disclosure:
|
|
2015 |
|
2014 |
|
in US$ million (unaudited) |
|
Q2 |
|
Q1 |
|
FY |
|
Q4 |
|
Q3 |
|
Q2 |
|
Q1 |
|
Net revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
4,199 |
|
3,960 |
|
15,832 |
|
4,320 |
|
4,113 |
|
3,835 |
|
3,564 |
|
Net Health Care |
|
3,345 |
|
3,182 |
|
12,250 |
|
3,322 |
|
3,197 |
|
2,949 |
|
2,782 |
|
Dialysis products |
|
854 |
|
778 |
|
3,582 |
|
998 |
|
916 |
|
886 |
|
782 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
2,946 |
|
2,771 |
|
10,500 |
|
2,876 |
|
2,710 |
|
2,521 |
|
2,393 |
|
Net Health Care |
|
2,722 |
|
2,571 |
|
9,655 |
|
2,640 |
|
2,498 |
|
2,316 |
|
2,201 |
|
Thereof Net Care Coordination revenue |
|
468 |
|
434 |
|
1,039 |
|
395 |
|
307 |
|
188 |
|
149 |
|
Thereof Net Dialysis Care revenue |
|
2,254 |
|
2,137 |
|
8,616 |
|
2,245 |
|
2,191 |
|
2,128 |
|
2,052 |
|
Dialysis products |
|
224 |
|
200 |
|
845 |
|
236 |
|
212 |
|
205 |
|
192 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International |
|
1,247 |
|
1,180 |
|
5,265 |
|
1,422 |
|
1,386 |
|
1,297 |
|
1,161 |
|
Net Health Care |
|
623 |
|
611 |
|
2,595 |
|
682 |
|
699 |
|
633 |
|
581 |
|
Dialysis products |
|
624 |
|
569 |
|
2,670 |
|
740 |
|
687 |
|
664 |
|
580 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EMEA |
|
668 |
|
629 |
|
3,072 |
|
766 |
|
784 |
|
790 |
|
732 |
|
Net Health Care |
|
309 |
|
301 |
|
1,438 |
|
342 |
|
367 |
|
371 |
|
357 |
|
Dialysis products |
|
359 |
|
328 |
|
1,634 |
|
424 |
|
417 |
|
419 |
|
375 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia-Pacific |
|
376 |
|
353 |
|
1,357 |
|
419 |
|
387 |
|
309 |
|
243 |
|
Net Health Care |
|
164 |
|
164 |
|
569 |
|
178 |
|
183 |
|
120 |
|
88 |
|
Dialysis products |
|
212 |
|
189 |
|
788 |
|
241 |
|
204 |
|
189 |
|
155 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Latin America |
|
203 |
|
198 |
|
836 |
|
237 |
|
215 |
|
198 |
|
186 |
|
Net Health Care |
|
150 |
|
146 |
|
588 |
|
162 |
|
149 |
|
142 |
|
136 |
|
Dialysis products |
|
53 |
|
52 |
|
248 |
|
75 |
|
66 |
|
56 |
|
50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate |
|
6 |
|
9 |
|
67 |
|
22 |
|
17 |
|
17 |
|
10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (EBIT) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
547 |
|
504 |
|
2,255 |
|
663 |
|
590 |
|
556 |
|
445 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
428 |
|
340 |
|
1,643 |
|
493 |
|
413 |
|
401 |
|
336 |
|
Care Coordination |
|
37 |
|
15 |
|
77 |
|
30 |
|
17 |
|
17 |
|
13 |
|
Dialysis |
|
391 |
|
325 |
|
1,566 |
|
463 |
|
396 |
|
384 |
|
323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International |
|
217 |
|
244 |
|
970 |
|
278 |
|
269 |
|
243 |
|
180 |
|
EMEA |
|
134 |
|
141 |
|
590 |
|
143 |
|
151 |
|
168 |
|
128 |
|
Asia-Pacific |
|
67 |
|
85 |
|
279 |
|
100 |
|
90 |
|
55 |
|
33 |
|
Latin America |
|
16 |
|
18 |
|
101 |
|
35 |
|
28 |
|
20 |
|
19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate |
|
-98 |
|
-80 |
|
-358 |
|
-108 |
|
-92 |
|
-88 |
|
-71 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delivered EBIT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
478 |
|
450 |
|
2,040 |
|
595 |
|
532 |
|
509 |
|
403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America |
|
362 |
|
288 |
|
1,436 |
|
428 |
|
358 |
|
355 |
|
295 |
|
Care Coordination |
|
24 |
|
6 |
|
57 |
|
19 |
|
13 |
|
14 |
|
10 |
|
Dialysis |
|
338 |
|
282 |
|
1,379 |
|
409 |
|
345 |
|
341 |
|
285 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International |
|
214 |
|
242 |
|
962 |
|
275 |
|
266 |
|
242 |
|
179 |
|
EMEA |
|
133 |
|
141 |
|
587 |
|
142 |
|
150 |
|
168 |
|
127 |
|
Asia-Pacific |
|
65 |
|
83 |
|
274 |
|
98 |
|
88 |
|
54 |
|
33 |
|
Latin America |
|
16 |
|
18 |
|
101 |
|
35 |
|
28 |
|
20 |
|
19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate |
|
-98 |
|
-80 |
|
-358 |
|
-108 |
|
-92 |
|
-88 |
|
-71 |
|
2
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024